HCP – Talicia

Prescribing Information
Patient Site
Sign up for emails
Request a representative

Approved use for Talicia

Talicia is indicated for the treatment of Helicobacter pylori infection in adults

About
- H. pylori resistance
- How Talicia works
Efficacy
- Talicia eradication rates
- Traditional therapy failure rates
Safety
Simple Dosing
HCP Resources

About
▽
- H. pylori resistance
- How Talicia works
Efficacy
▽
- Talicia eradication rates
- Traditional therapy failure rates
Safety
Simple Dosing
HCP Resources
▽

Slide

Eradication Starts Here^TM

Discover high eradication rates

Find out how your patients can save on Talicia

Request a representative

+ -

Important Safety Information

Talicia contains omeprazole, a proton pump inhibitor (PPI), amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial. It is contraindicated in patients with known hypersensitivity to any of these medications, any other components of the formulation, any other beta-lactams or any other rifamycins.

Talicia is contraindicated in patients receiving delavirdine, voriconazole or rilpivirine-containing products.

Serious and occasionally fatal hypersensitivity reactions have been reported with the components of Talicia: omeprazole, amoxicillin and rifabutin.

Severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the components of Talicia: rifabutin, amoxicillin, and omeprazole.

Acute Tubulointerstitial Nephritis has been observed in patients taking PPIs and penicillins.

Clostridioides difficile-associated diarrhea has been reported with use of nearly all antibacterial agents and may range from mild diarrhea to fatal colitis.

Talicia may cause fetal harm and is not recommended for use in pregnancy. It may also reduce the efficacy of hormonal contraceptives. An additional non-hormonal method of contraception is recommended when taking Talicia.

Talicia should not be used in patients with hepatic impairment or severe renal impairment.

Cutaneous lupus erythematosus and systemic lupus erythematosus have been reported in patients taking PPIs. These events have occurred as both new onset and exacerbation of existing autoimmune disease.

The most common adverse reactions (≥1%) were diarrhea, headache, nausea, abdominal pain, chromaturia, rash, dyspepsia, oropharyngeal pain, vomiting, and vulvovaginal candidiasis.

Please also see complete Prescribing Information.

HCP Address

RedHill Biopharma Inc. (U.S. Office)
8041 Arco Corporate Drive, Suite 200
Raleigh, NC 27617
Tel: +1-984-444-7010
Fax: +1-919-406-0400
info@redhillus.com

Contact Us
RedHill Biopharma US Corporate Site
Privacy Policy
Terms of Use
Sitemap
Sitemap
Prescribing Information

Trademarks are owned by or licensed to RedHill Biopharma Inc. or its related companies.

©2021 RedHill Biopharma Ltd. All rights reserved. US-TAL-139 06/2021

The information on the following site is intended for US health care professionals. Please choose:

I am not a US health care professional

I am a US health care professional

The information on the following site is intended for US health care professionals. Please choose:

I am not a US health care professional

I am a US health care professional